Xilio Therapeutics (NASDAQ:XLO – Get Rating) had its price target lowered by Raymond James from $31.00 to $13.00 in a research report sent to investors on Thursday morning, Benzinga reports. The firm currently has an outperform rating on the stock.
Separately, Morgan Stanley dropped their price target on Xilio Therapeutics from $32.00 to $20.00 and set an overweight rating on the stock in a research report on Wednesday, August 10th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Xilio Therapeutics currently has a consensus rating of Buy and a consensus target price of $16.50.
Get Xilio Therapeutics alerts:Xilio Therapeutics Stock Performance
Shares of XLO stock traded up $0.15 on Thursday, hitting $2.44. 12,826 shares of the stock traded hands, compared to its average volume of 25,352. The company has a debt-to-equity ratio of 0.04, a current ratio of 9.17 and a quick ratio of 9.17. The company has a market capitalization of $67.03 million and a PE ratio of -0.72. Xilio Therapeutics has a 1-year low of $2.01 and a 1-year high of $27.95. The company's fifty day moving average is $2.54 and its 200 day moving average is $2.77.
Xilio Therapeutics (NASDAQ:XLO – Get Rating) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.12). On average, equities research analysts predict that Xilio Therapeutics will post -3.49 earnings per share for the current fiscal year.Institutional Investors Weigh In On Xilio Therapeutics
Several large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp increased its position in Xilio Therapeutics by 47.7% in the first quarter. Bank of New York Mellon Corp now owns 21,029 shares of the company's stock worth $149,000 after buying an additional 6,791 shares during the period. State Street Corp grew its stake in shares of Xilio Therapeutics by 58.5% in the first quarter. State Street Corp now owns 93,861 shares of the company's stock worth $664,000 after purchasing an additional 34,651 shares in the last quarter. Bailard Inc. bought a new position in shares of Xilio Therapeutics in the second quarter worth $107,000. Millennium Management LLC bought a new position in shares of Xilio Therapeutics in the second quarter worth $146,000. Finally, Renaissance Technologies LLC bought a new position in shares of Xilio Therapeutics in the second quarter worth $220,000. 64.66% of the stock is owned by institutional investors and hedge funds.
About Xilio Therapeutics
(Get Rating)
Xilio Therapeutics, Inc, a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors.
Featured Articles
- Get a free copy of the StockNews.com research report on Xilio Therapeutics (XLO)
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don't Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.